Introduction

Melorheostosis, also known as Leri disease, is a rare bone disorder. It is an unusual mesenchymal dysplasia that shows up as areas of sclerosing bone that resemble drippy wax.⁷ It is when there is excessive cortical bone tissue deposition around existing bone tissue. 

As a result of the classic radiographic look of "flowing hyperosteosis," which resembles solidified wax that has leaked down a candle's side, the term melorheostosis is derived from the Greek words melos, which means limb, and rheos, which means flow. There currently is no known genetic trait, and no sex-specific effect. Childhood is when the illness first manifests. The most prevalent symptom is pain, and it develops slowly at first. Rarely is the axial skeleton found in bones, although the diaphysis of the long bone of the lower limb is the most prevalent type. In addition, it may manifest as ossification in nearby soft tissues, joint stiffness, increasing deformity, and discrepancy in limb length. The precise etiology of the disease is unclear.¹

Epidemiology

Although alterations start in early childhood, melorheostosis frequently doesn't manifest until later in adolescence or the early stages of life. The diagnosis is made before the age of 22 in only around half of the cases.

No discernible variations in familial tendency have been observed.

Symptoms are as such:

• Changes in sclerodermic skin: fibrosis and thickening of the skin layer above
• Hyperpigmentation of the skin layer above
• Muscle wasting
• Vascular malformations and tumors
• Various cancers, such as malignant fibrous histiocytoma and osteosarcoma
• The Buschke-Ollendorff phenomenon²

Etiology

Typically, melorheostosis is a solitary illness. However, it has also been noted in certain families with Buschke-Ollendorff syndrome or osteopoikilosis, as a result of, a mutation or harmful variation in the LEMD3 gene.

Melancholy may result from a somatic mutation because the disease manifests intermittently, there are no instances of it being inherited by offspring, and the distribution of bone lesions is confined. Somatic mutations are DNA alterations that happen post-conception; as a result, they are not found in sperm or eggs and are not inherited by offspring.

The SMAD3 and MAP2K1 genes have been shown to have somatic mutations. Additionally, there are hints that somatic mutations in additional unidentified genes might be the cause of the illness.⁴

Pathology

Melorheostosis tends to be monomeric and can be either polyostotic or monostotic. Though it can be observed practically anywhere, it prefers lengthy bones in the limbs. While the axial skeleton is rarely affected, the hands and feet are usually impacted.^1,2 A sclerotome distribution is more likely to result from the syndrome. Rarely, a mineralized periarticular mass may be found.²

Clinical presentation

It is a rare that meleoheostosis affects both sides of the body. Instead, it typically affects one arm or leg (a section of the appendicular skeleton). Usually, this is limited to the lateral (outside) or medial (inside) of the bones. Additionally, the axial skeleton - the pelvis, sternum, ribs, and, less frequently, the spine and skull - may be impacted by the illness. Over time, symptoms could get worse and worse. Melelorheostosis symptoms and signs might include:

• Abnormal bone development, characterized by "dripping" and thickening of the cortex
• Look of "candle wax" on x-ray pictures (This indication manifests as irregular cortical bone hyperostosis, resembling melted wax cascading down one side of a candle.)
• Leg-length disparity, or the difference in length between two legs or arm
• Soft tissue anomalies include: Ligament and tendon shortening
• Muscles that are aberrant or absent
• Tissue accumulation of calcium (subcutaneous calcification)
• Joint contractures and edema resulting in deformed or immobile joints
• Restricted range of motion
• Stiffness and pain
• Arms and legs swelling (edema) (extremities)
• Abnormalities in the veins
• Bone injuries causing nerve compression (less common but dangerous)

The most noticeable sign in children is a difference in limb length accompanied by malformed joints and joint contractures.

Pain, stiff joints, and increasing deformity are more noticeable in adulthood.

The course of melorheostosis is chronic. In general, symptoms start in early childhood and may even appear in the earliest stages of life, albeit the severity of onset and symptoms vary widely between children and adults. By the time they are 20 years old, about 50% of melorheostosis patients will have symptoms.

Complications stem from the injury spreading to nearby soft tissues, as well as from bone deformation and structural damage. There also have been reports on the possibility of tissue cells developing into cancer.⁴

Diagnosis

Imaging tests such as these are used by medical professionals to diagnose melorheostosis:

• Imaging scans and little doses of radioactive material injected are used in bone scans
• Safe, low radiation dosages are used in X-rays to see soft tissues and bones. On an X-ray, your bones will appear to be "dripping wax" if you have melorheostosis because thick hyperostosis runs over the bone's cortex.
• The assessment of soft tissue injuries benefits from the use of magnetic resonance imaging (MRI). Although it is not commonly used to diagnose melorheostosis, MRI can show bone marrow invasion.
• A biopsy reveals highly uneven bones with mixed sections of lamellar and woven bone, as well as varied degrees of fibrosis in the bone marrow - the area inside the body's bones where blood cells are created.

Prognosis

Melorheostosis has no harmful effects on life expectancy and is not malignant. However, it may restrict your range of motion. You can get edema or joint pain. A better quality of life can be achieved by melorheostosis patients with the appropriate treatment plan.⁶

Differential diagnosis

• Multiple round or oval patches of increased bone density at the ends of the long bones are the hallmark of the uncommon and benign bone disease known as osteopoikilosis. Typically, they are found bilaterally, or on both sides of the body.
• Osteopoikilosis and skin growths known as connective tissue naevi are the hallmarks of Buschke-Ollendorff syndrome, a rare hereditary connective tissue condition.
• Cancers of the bone that contain thick bone tissue, such osteosarcoma, a kind of bone cancer that starts in the cells that form bones.
• A benign bone condition called striated osteopathy is typified by longitudinal striations - stronger densities - in the afflicted bones.
• Myositis ossificans progressiva, often called fibrodysplasia ossificans progressiva, is a heritable connective tissue illness that causes significant disability.

Treatment and management

There are currently few treatments available, most of which focus on symptom reduction.

• Due to the tiny number of people diagnosed globally, there are currently no treatment guidelines based on scientific data. For some people, what works well may not work at all or even be detrimental. Treatment must thus be customized for each patient and necessitates the collaboration of a multidisciplinary team of experts. The degree of skeletal involvement, therapeutic options, and symptom severity should all be taken into consideration while choosing a course of treatment.
• Surgery, physical and occupational therapy, hydrotherapy, and drugs that interfere with the process of bone remodelling are among possible treatment options.
• Since many patients with this disease have no symptoms, nonsurgical treatment is frequently enough to reduce symptoms and return function.
• Managing pain can be difficult. Nonsteroidal anti-inflammatory medicines (NSAIDs), steroids, and, in rare cases, opioids are examples of prescription pain relievers. Sometimes, in the early stages of the disease, these drugs are beneficial.
• Other non-pharmacological treatments have also been employed, including nerve blocks, which involve injecting an anesthetic and/or anti-inflammatory drug to target a particular nerve or group of nerves in order to treat pain; serial casting; manipulations; and sympathectomies, which entail cutting or blocking a central nervous system nerve.
• Drugs called denosumab and zolendronate improved symptoms in a few isolated patients.

Research

Future research on melorheostosis will primarily address a number of questions, most pertaining to the etiology and treatment of the disease. A clinical staging system may be developed, and further genetic and clinical characterization of the disease's progression is necessary. One study found that, after a 24-year follow-up, a case of melorheostosis in the left arm was strictly limited to a dermatome supplied by the associated spinal nerve. Additional longitudinal studies are required to confirm the etiology of melorheostosis. The variable symptomatology and rarity of melorheostosis pose a significant obstacle to identifying the cause of the condition. The "dripping candle wax" appearance is not universally observed, as evidenced in only five of the 24 cases in the Mayo Clinic's retrospective study. Studies ought to compare the results of surgery with stand-alone pharmaceutical treatment. Numerous pharmaceutical approaches have been considered, including nifedipine, denosumab, and the more well-known bisphosphonates. The investigation of melorheostosis's vascularity is supported by nifedipine.

Summary

In conclusion, melorheostosis in children is a rare skeletal disorder that significantly impacts growth, development, and quality of life. Characterized by abnormal bone thickening, it leads to pain, stiffness, and potential deformities. Early diagnosis and a multidisciplinary approach to treatment are crucial. This includes pain management, physical therapy, and, in some cases, surgical intervention to correct severe deformities or alleviate nerve compression. Continuous monitoring and support are essential to address the physical and emotional challenges faced by affected children. Ongoing research holds promise for more targeted treatments in the future, aiming to improve outcomes and quality of life for young patients with melorheostosis.